At 4 and 24 weeks after the second booster, CD4+ T cells continued to respond to the COVID-19 antigens (S, S1, and NMO), whereas CD8+ T cell responses were no longer detectable (Table 2). The gene discussed is CD4; the disease is neuromyelitis optica.